ABSTRACT
Approximately 33% of melanomas are derived directly from benign, melanocytic nevi. Despite this, the vast majority of melanocytic nevi, which typically form as a result of BRAFV600E-activating mutations, will never progress to melanoma. Herein, we synthesize basic scientific insights and data from mouse models with common observations from clinical practice to comprehensively review melanocytic nevus biology. In particular, we focus on the mechanisms by which growth arrest is established after BRAFV600E mutation. Means by which growth arrest can be overcome and how melanocytic nevi relate to melanoma are also considered. Finally, we present a new conceptual paradigm for understanding the growth arrest of melanocytic nevi in vivo termed stable clonal expansion. This review builds upon the canonical hypothesis of oncogene-induced senescence in growth arrest and tumor suppression in melanocytic nevi and melanoma.
Subject(s)
Gene Expression Regulation, Neoplastic , Melanocytes/pathology , Melanoma/pathology , Mutation , Nevus, Pigmented/pathology , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/pathology , Animals , Cell Proliferation/genetics , Epigenomics , Humans , Melanoma/genetics , Mice , Models, Animal , Nevus, Pigmented/genetics , Signal Transduction , Skin Neoplasms/geneticsABSTRACT
Melanoma progression is typically depicted as a linear and stepwise process in which metastasis occurs relatively late in disease progression. Significant evidence suggests that in a subset of melanomas, progression is much more complex and less linear in nature. Epidemiologic and experimental observations in melanoma metastasis are reviewed here and are incorporated into a comprehensive model for melanoma metastasis, which takes into account the varied natural history of melanoma formation and progression.